Christopher Ferenc, an associate in the Intellectual Property practice, spoke with BioPharm Insight regarding inter partes review (IPR) proceedings, which employ a different set of standards than litigation since they lack the presumption of validity. Christopher notes that from the perspective of a patent challenger, IPR proceedings could therefore make patents easier to invalidate. (“Lilly Could Attempt Inter Partes Review Route to Hasten Insulin Glargine Approval in Legal Action Against Sanofi – Attorneys,” February 27, 2014)